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BACKGROUND Candida glabrata ranks second in epidemiological surveillance studies, and is considered one of the main human 
yeast pathogens. Treatment of Candida infections represents a contemporary public health problem due to the limited availability 
of an antifungal arsenal, toxicity effects and increasing cases of resistance. C. glabrata presents intrinsic fluconazole resistance 
and is a significant concern in clinical practice and in hospital environments.
OBJECTIVE The aim of this study was to characterise the azole resistance mechanism presented by a C. glabrata clinical isolate 
from a Brazilian university hospital.
METHODS Azole susceptibility assays, chemosensitisation, flow cytometry and mass spectrometry were performed.
FINDINGS Our study demonstrated extremely high resistance to all azoles tested: fluconazole, voriconazole, posaconazole and 
itraconazole. This isolate was chemosensitised by FK506, a classical inhibitor of ABC transporters related to azole resistance, 
and Rhodamine 6G extrusion was observed. A mass spectrometry assay confirmed the ABC protein identification suggesting 
the probable role of efflux pumps in this resistance phenotype.
MAIN CONCLUSIONS This study emphasizes the importance of ABC proteins and their relation to the resistance mechanism in 
hospital environments and they may be an important target for the development of compounds able to unsettle drug extrusion.
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The Candida genus is present as a commensal or-
ganism in approximately 25-75% of healthy individuals. 
However, Candida species are opportunist pathogens 
and responsible for approximately 90% of invasive in-
fections (Pfaller & Diekema 2007). Candidiasis is a per-
sistent infection and commonly observed in individuals 
infected with human immunodeficiency virus (HIV) as 
well as patients undergoing transplantation procedures 
(Yang et al. 2012, Marukutira et al. 2014). These infec-
tions are usually attributed to Candida albicans. Nev-
ertheless, Candida glabrata ranks second in epidemio-
logical surveillance studies, and is considered one of the 
main human yeast pathogens (Marukutira et al. 2014, 
Muadcheingka & Tantivitayakul 2015). Treatment for 
candidiasis is a serious problem for contemporary medi-
cine due to: a limited arsenal of antifungal drugs, toxic-
ity and an increasing number of resistant cases (Pfaller 
& Diekema 2007, Silva et al. 2012, Catalano et al. 2013). 
Many C. glabrata clinical isolates present low suscep-
tibility to fluconazole (FCZ), a common azole used for 
candidiasis treatment that targets the fungal specific 
ergosterol biosynthetical pathway (Ostrosky-Zeichner 
et al. 2003, Pfaller et al. 2004). This resistance pheno-
type can occur due to an alteration of the target enzyme 
(Erg11p) by mutation or overexpression of the ERG11 
gene leading to decreased drug efficacy (Moye-Rowley 
2015). Furthermore, azole resistance can be enhanced by 
efflux pumps, such as ABC protein transporters, a pri-
mary transporter that uses ATP hydrolysis as a source of 
energy to transport its substrates (CgCdr1p, CgCdr2p or 
CgPdh1p, CgSnq2p) (Sanglard et al. 1995, Vermitsky & 
Edlind 2004, Torelli et al. 2008). The aim of the present 
study is to evaluate if ABC transporters overexpression 
is related to the resistance phenotype of a C. glabrata 
clinical isolate previously selected from a total of 93 
Candida spp. samples isolated from the University Hos-
pital of the Federal University of Juiz de Fora, Minas 
Gerais (MG), Brazil, due to its high azole resistance.
MATERIALS AND METHODS
Clinical isolates and control strains - Three resis-
tant and one susceptible C. glabrata clinical isolate were 
selected from ninety-three Candida strains due to their 
high/low fluconazole (FCZ) resistance (Neves-Junior et 
al. 2015). These clinical isolates were obtained from pa-
tients attended at the University Hospital of the Federal 
University of Juiz de Fora, MG, Brazil, between 2012 
and 2014. The Candida isolates were isolated from clini-
cal materials obtained from ambulatory patients or from 
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patients in intensive care (ICU). These clinical materials 
were mainly urine, feces, catheter, blood and other secre-
tions. The ethical use of these materials was approved by 
Protocol CEP-UFJF: 079-420-2010-FR:368108; CAEE: 
0056.420.000-10. Five mutant strains of Saccharomy-
ces cerevisiae, kindly donated by Drs Richard Cannon 
and Brian Monk (University of Otago - New Zealand), 
were used: one null mutant, deleted all the genes that en-
coded efflux pumps; AD/CaCDR1 S. cerevisiae mutant 
strain that overexpresses C. albicans ABC transporter, 
CaCdr1p; AD/CgCDR1 S. cerevisiae mutant strain that 
overexpresses C. glabrata ABC transporter, CgCdr1p; 
AD/CgDR2 (AD/PDH1) S. cerevisiae mutant strain that 
overexpresses C. glabrata ABC transporter, CgCdr2p; 
and AD/124567 S. cerevisiae mutant strain that over-
expresses Pdr5p of S. cerevisiae (Lamping et al. 2007). 
ATCC 2001 C. glabrata was also used as control for 
tests using Candida strains.
Yeast culture conditions - Candida strains were grown 
in YPD medium (2% glucose, 2% peptone, 1% yeast ex-
tract) at 37ºC under agitation, and were harvested in the 
exponential phase of growth. S. cerevisiae mutant strains 
were grown under the same conditions at 30ºC.
Strain identification - Identification of the Candida 
spp. clinical isolate was carried out using MALDI Mi-
croflex LT (Bruker Daltonics, Bremen, Germany) with 
the formic acid extraction procedure according to the 
manufacturer. Briefly, a single colony of each strain 
grown overnight in YPD agar was suspended in 300 µL 
of de-ionised water and 900 µL of absolute ethanol and 
centrifuged at 24000 x g for 2 min. The supernatant was 
discarded and the pellet was air-dried, ressuspended in 
70% formic acid and 100% acetonitrile and vortexed. 
The samples were centrifuged at 14462 x g for 2 min, 
and 1 µL of supernatant, in duplicate, was spotted onto 
a steel target and air-dried at room temperature. Be-
fore identification, each spot was overlaid with 1 µL of 
HCCA (α-Cyano-4-hydroxycinnamic acid, Bruker) ma-
trix solution saturated with 50% acetonitrile and 2.5% 
trifluoroacetic acid, and then completely air dried. The 
spectra were calibrated externally using a standard cali-
brant ATCC Escherichia coli 25922, before plate identi-
fication. Raw spectra were analysed using MALDI BIO-
TYPER Real-time Classification software version 3.1 
(Bruker Daltonik MALDI Biotyper). Strains with scores 
≥ 2 were considered as reliable species identification.
Azole susceptibility tests - In vitro susceptibility 
tests were performed according to the Clinical Labora-
tory Standards Institute (CLSI) M27-A3 protocol by the 
broth microdilution assay (CLSI 2008). According to the 
CLSI protocol, FCZ minimal inhibitory concentration 
(FCZ MIC50) end points ≤ 8 µg/mL were categorised as 
susceptible (S); MIC50 end points between 16 and 32 µg/
mL were classified as susceptible dose-dependent (SDD), 
and resistant (R) strains obtained MIC50 end points ≥ 64 
µg/mL. For itraconazole (ITZ), the MIC50 end points ≤ 
0.125 µg/mL were classified as susceptible, MIC50 end 
points between 0.25 - 0.5 µg/mL were categorised as SDD 
and R isolates for end points ≥ 1 µg/mL. For voriconazole 
(VRZ) the MIC50 end points ≤ 1 µg/mL were classified as 
S, MIC50 end points ≥ 2 µg/mL were categorised as SDD 
and R isolates for end points ≥ 4 µg/mL. For posaconazole 
(PSZ) 0 - 8 µg/mL concentrations were tested. Clinical 
breakpoints for PSZ concentrations have not been pro-
posed yet, but the values are considered to be close to the 
ITZ breakpoints for C. albicans. Cell growth analyses 
were performed by microplate reader at 600 nm (Fluostar 
Optima, BMG Labtech, Offenburg, Germany).
Evaluation of azole resistance reversion by FK506 
- FK506 is a classical ABC transporter inhibitor (Egner 
& Kuchler 2000) and is used as a screening for resistance 
mediated by these efflux proteins. The “spot test” was 
used as a measure of growth as previously described by 
(de Sá et al. 2014). Screenings of azole resistance concen-
trations were previously performed in order to observe 
the highest azole concentrations that did not affect yeast 
viability. We tested 5 - 200 µg/mL of FCZ and 1 - 50 µg/
mL of ITZ, 0.1 - 20 µg/mL of VRZ and 0.5 - 100 µg/mL of 
PSZ for clinical isolates and mutant S. cerevisiae strains.
For S. cerevisiae strains, 5 μL samples of fivefold 
serially diluted yeast cultures (initially suspended to an 
OD of 0.1) were spotted on YPD agar in 6 well sterile 
polystyrene plates. They were incubated in the pres-
ence of different azoles concentrations. Controls were 
performed using YPD alone and YPD supplemented 
with: azole, azole + 0.5% DMSO, azole + 10 μM FK506. 
Plates were incubated at 30ºC for 48 h.
In the case of C. glabrata, the same methodology 
was used, but with some adaptations: 5 μL of a five-fold 
serial dilution from a yeast suspension containing 6 x 105 
cells/mL was spotted on Sabouraud agar supplemented 
with the compounds at 100 μM alone or combined with 
different azoles concentrations. The incubation of the six 
well plates was carried at 37ºC for 48 h.
Flow cytometry assay - The experiment was per-
formed using seven yeast strains: four S. cerevisiae mu-
tant strains (null mutant, AD/CaCDR1, AD/CgCDR1, 
AD/CgCDR2), one susceptible C. glabrata (S) clinical 
isolate (code 227i), one C. glabrata (R) FCZ resistant 
clinical isolate (code 109) and one ATCC C. glabrata 
(code ATCC 2001). Then 1 x 10³ cells/mL were incubated 
overnight in 20 mL of YPD medium at 37ºC under agita-
tion. After incubation, with values varying between OD 
1 to 3, the cells were centrifuged at 5000 x g for 5 min 
and washed four times with deionised water. After wash-
ing, the strains were maintained on ice for 2 h, then 6 x 
105 cells/mL were incubated with 5 µM of rhodamine 6G 
(R6G), an ABC transporter fluorescent substrate (Mae-
saki et al. 1999), in the presence or absence of 2% glucose 
for 1 h, at 37ºC under agitation. The cells were centri-
fuged at 9000 x g for 2 min and washed three times with 
phosphate buffer saline (PBS) before analysis in duplicate 
by BD Accuri™ C6 Flow Cytometer to measure the R6G 
efflux by strains. Data analysis was conducted using Ac-
curi™ C6 Software (Accuri Cytometers - v. 1.0.264.21).
Preparation of plasma membranes - Yeast plasma 
membrane isolates from clinical and mutant yeast strains 
were obtained as previously described by (Rangel et al. 
2010). The plasma membrane preparations were stored 
in liquid nitrogen and thawed just before use.
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Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) - Protein samples were subjected 
to 10% SDS-PAGE (Laemmli 1970). Protein bands were 
visualised by staining with Coomassie brilliant blue 
R-250 (Sigma). The protein concentration was measured 
using the Bradford assay (Bradford 1976).
In-gel digestion - Approximately 30 µg of total pro-
teins obtained from membrane isolation were loaded 
onto 10% SDS-PAGE, followed by Coomassie Brilliant 
blue staining. The sample-containing band, around 160 
KDa, was cut and submitted to the trypsinisation process. 
Each band excisions, from controls and clinical isolate 
samples, were de-stained with 25 mM NH4HCO3 in 50% 
acetonitrile for 16 h. The excised bands from the non-
reduced gels were reduced using 10 mM dithiothreitol 
(DTT) in 25 mM NH4HCO3 solution to completely cover 
gel pieces and incubated for 1 h at 56ºC. The samples 
were alkylated with 55 mM iodoacetamide in 25 mM 
NH4HCO3 and incubated for 45 min at room temperature 
in the dark. After which the solution was removed and 
the spots were washed with 25 mM NH4HCO3 solution 
in 50% acetonitrile and then dehydrated with 100% ace-
tonitrile. A solution of 25 mM NH4HCO3 containing 100 
ng trypsin gold (Promega) was added to cover the dried 
gel pieces. The samples were digested overnight at 37ºC. 
The tryptic peptides were extracted from SDS-PAGE gel 
using 50% acetonitrile in 0.1% formic acid solution.
Ultra-high performance liquid chromatography 
(UHPLC)-MS/MS mass spectrometry - electrospray ioni-
sation (ESI) - The extracted peptides from the SDS-PAGE 
gel spots were desalted on-line using a Waters Opti-Pak 
C18 trap column. The sample injection volume was fixed 
at 45 µL and the UHPLC was performed using a C18 
150mm x 2mm column (SHIMADZU), eluted (300 µL/
min) with a linear gradient (3-45%) of acetonitrile con-
taining 0.1% formic acid. Electrospray tandem mass spec-
tra were recorded using an ESI - Ion Trap spectrometer 
(AmaZon SL). The ESI capillary voltage was set at 4,500 
V and the source temperature was 300ºC. The end plate 
offset was 500 V. Data acquisition were conducted by 
TrapControl software (version 7.0, Bruker); experiments 
were performed by scanning from a mass-to-charge ra-
tio (m/z) of 300 - 1,500 using a scan speed 8,100 m/z per 
second, applied during the whole chromatographic pro-
cess. The mass spectra corresponding to each signal from 
the total ion current (TIC) chromatogram were averaged. 
Data dependent MS/MS acquisitions were performed on 
precursors with charge states of 2, 3 or 4 over a range of 
100 - 2000 m/z and under a 4 m/z window. Collision in-
duced dissociation (CID) MS/MS spectra were obtained 
using helium as the collision gas. All data were processed 
using Compass Data Analysis (version 1.3 SR2, Bruker).
Mass spectrometry data analysis - The proteins were 
identified by analysing the precursor and fragmentation 
spectra using MASCOT software (Matrix Science, ver-
sion 2.1). One missed cleavage per peptide was allowed 
and an initial mass tolerance of 0.5 Da was used in all 
searches. Cysteines were assumed to be carbamidometh-
ylated and a variable modification of methionine (oxida-
tion) was allowed.
RESULTS
Clinical source and species identification - After a 
screening of 93 Candida spp. clinical isolates provided 
by the University Hospital of the Federal University of 
Juiz de Fora, MG, Brazil, between 2012 and 2014 (Neves-
Junior et al. 2015), four strains were selected: three R 
strains (codes 107, 109 and 211i) and one S (code 227i) 
to antifungal FCZ. All clinical isolates were identified as 
C. glabrata specie by MALDI-TOF mass spectrometry 
analysis. These three strains were selected due to the low 
fluconazole susceptibility observed in C. glabrata specie.
Azole susceptibility - Selected C. glabrata strains 
were previously classified as S, susceptible-dependent 
dose (SDD) and R to FCZ according to the CLSI M27-
A3 protocol (CLSI 2008, Neves-Junior et al. 2015). In 
the present study, other azoles such as ITZ, PSZ and 
VRZ, in different concentrations, were also tested. We se-
lected three C. glabrata fluconazole resistant strains that 
had been previously chemosensitised by FK506, a classic 
ABC transporter inhibitor (Neves-Junior et al. 2015). As 
observed in Table I, only C. glabrata presented a high re-
sistant phenotype to all azoles tested: MIC50 breakpoints 
were higher than the last concentration tested in this study. 
According to the CLSI-M27-A3 protocol, 109 strain was 
also considered resistant to ITZ (≥ 1 µg/mL) and VRZ 
(≥ 4 µg/mL). This clinical isolate presented cell growth 
at the maximum PSZ concentration tested (≥ 8 µg/mL). 
This C. glabrata strain (code 109) was selected for further 
experiments due to its high resistant profile in comparison 
to the other FCZ resistant clinical isolates: 107 and 211i. 
The FCZ susceptible clinical isolate (code 227i) and the 
ATCC C. glabrata strain (ATCC 2001 C. glabrata) were 
also considered susceptible to all azoles tested.
Reversion of azole resistance - The chemosensiti-
sation assay using FK506 and different azoles was per-
formed in order to evaluate the possible resistance mecha-
nism of the 109 strain. S. cerevisiae mutant strains were 
also used as controls (Fig. 1, Table II). Several concentra-
tions of FCZ, ITZ, VRZ and PSZ were tested in solid YPD 
(S. cerevisiae) or Sabouraud (Candida isolates) medium 
TABLE I
Minimum inhibitory concentration (MIC50) of resistant  
and susceptible to fluconazole (FCZ), itraconazole (ITZ),  
voriconazole (VRZ) and posaconazole (PSZ) Candida glabrata 










C. glabrata (R) 109 > 1000 > 2 > 8 > 8
C. glabrata (R) 107 > 1000 > 1 < 0.5 > 8
C. glabrata (R) 211i > 250 > 2 < 1 < 1
C. glabrata (S) 227i < 8 < 0.125 < 0.250 < 1
C. glabrata ATCC 2001 < 8 < 1 < 0.5 < 0.5
*: values in µg/mL; R: resistant; S: susceptible.
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and none of them affected cell growth (data not shown). 
Each azole was used in different concentrations in com-
bination with FK506 according to each specie and strain. 
For this test, It was selected the concentration of azole that 
did not affect cell viability. Resistant strains presented re-
sistance phenotype reverted after incubation with FK506 
and FCZ. Null mutant, a S. cerevisiae mutant strain that 
does not present any efflux pumps proteins, was suscep-
tible to low doses of FCZ (8 µg/mL). Similar susceptibility 
was observed in clinical isolate C. glabrata (S) and ATCC 
2001 for FCZ in the same concentration.
Table II provides a summary of several chemosensi-
tisation assays using different azoles (ITZ, VRZ, PSZ). 
Note that the null mutant strain, 227i strain and C. gla-
brata ATCC2001 were susceptible to the lowest azole 
concentration used, as a consequence, the azole combi-
nation with FK506 did not lead to cell growth (-). For 
resistant mutant strains (AD/CaCDR1, AD/CgCDR1, 
AD/CgCDR2) and 109 clinical isolate, the maximum 
concentration tested in previous screening did not affect 
cell growth, meanwhile, this same concentration in com-
bination with FK506 provoked cell death (Table II).
Flow cytometry analysis - A flow cytometry assay 
was performed in order to observe the extrusion of R6G, 
a fluorescent substrate of ABC transporters, by resistant 
and susceptible strains. Four S. cerevisiae strains were 
used as controls: one susceptible (null mutant) and three 
FCZ resistant (AD/CaCDR1, AD/CgCDR1, AD/CgC-
DR2) (Fig. 2). The S. cerevisiae FCZ resistant controls 
were able to pump out R6G in the presence of glucose 
while the null mutant presented approximately 96% of 
intracellular fluorescence in the absence and presence of 
glucose. The 109 clinical isolate extruded R6G signifi-
cantly: in the absence of glucose (-), the intracellular ac-
cumulation of R6G was 78%, and in the presence of glu-
cose (+) only 46% was fluorescent. A similar significant 
extrusion was observed in S. cerevisiae AD/CgCDR1 
(glucose (-) 84% of fluorescence and glucose (+), 51%). It 
is important to note that susceptible controls 227i strain 
and ATCC C. glabrata did not extrude the fluorescent 
probe significantly after glucose incubation. These re-
sults confirm those obtained by the chemosensitisation 
assay once reverted strain pumped out R6G (Fig. 2).
UHPLC-MS/MS mass spectrometry - ESI - MS 
analysis was performed in order to identify the ABC 
transporter protein in susceptible strains samples (null 
mutant, 227i strain and C. glabrata ATCC2001) and 
azole resistant S. cerevisiae strains (AD/CgCDR1, AD/
CgCDR2 and 109 strain). Another S. cerevisiae mutant 
strain (AD/124567) overexpressing its own ABC trans-
porter, Pdr5p, was used as control in this experiment. 
Plasma membrane preparation of each yeast strain was 
separated by SDS PAGE (Fig. 3A). As expected, the 
Fig. 1: chemosensitisation assay using FK506 in the presence or ab-
sence of fluconazole (FCZ). Saccharomyces cerevisiae mutant cells 
were used as control: null mutant, AD/CaCDR1, AD/CgCDR1 and 
AD/CgCDR2 (CgPdh1). Different FCZ concentrations were used in 
each strain: null mutant, Candida glabrata (S), C., ATCC2001 8 µg/
mL; AD/CaCDR1 and AD/CgCDR1 160 µg/mL; AD/CgCDR2 20 µg/
mL; C. glabrata (R) 100 µg/mL. FK506 (10 µM).
TABLE II
Summary of chemosensitisation assays using FK506 in the presence or absence of different azoles: itraconazole (ITZ), 
voriconazole (VRZ) and posaconazole (PSZ). The positive and negative signals indicate growth or absence of cell growth, 
respectively. FK506 (10 µM)






















ITZ+FK - - - - - - -















VRZ+FK - - - - - - -















PSZ+FK - - - - - - -
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ABC transporter of null mutant (lane 1) was not visu-
alised by SDS-PAGE neither the MS/MS analysis. ABC 
proteins were observed in all the resistant mutants and 
clinical strains (lanes 2, 3, 4 and 5, approximately 160 
kDa). It is worth mentioning that the susceptible clinical 
strain (227i isolate, lane 6) and C. glabrata ATCC2001 
(lane 7) did not present a detectable band. ESI-MS/MS 
analysis of the excised band from the 109 strain plas-
ma membrane preparation resulted in three different 
m/z peaks of 536.8 (corresponding to a charge of +1), 
532.8 (corresponding to a charge of +2) and 639.9 (cor-
responding to a charge of +2) (Fig. 3B). The identified 
peptides were R.ASSIFSADFK.G, K.NEYVEAVIK.I 
and R.GLDSATALEFVR.A. The Mascot analysis of 
these three peptides identified the ABC transporter 
protein CgCdr1 (Fig. 3C). The excised band from con-
trols, AD/124567 (lane 2), AD/CgCDR1 (lane 3) and 
AD/CgCDR2 (lane 4), were analysed by ESI- MS/MS 
and corresponded to more than 10 peptides of the ABC 
transporter proteins (data not shown) (Fig. 3).
DISCUSSION
C. glabrata is the second most common cause of 
mucosal and blood-stream candidiasis, it ranks in epide-
miological surveillance studies after C. albicans and it 
is considered as one of the main human yeast pathogens 
(Pfaller & Diekema 2007, Muadcheingka & Tantivita-
yakul 2015). Azoles, mainly FCZ, are by far the most 
commonly used antifungal drug in clinical practice but, 
in previous decades, there have been many cases of re-
sistance to antifungal agents used in the prophylaxis and 
treatment of Candida species infections (Almeida et al. 
2013, Jiang et al. 2013).
C. glabrata usually presents low FCZ susceptibil-
ity, the most common azole used in candidiasis treat-
ment (8-27% of isolates demonstrate a MIC50 ≥ 64 µg/
mL) (Ostrosky-Zeichner et al. 2003, Pfaller et al. 2004, 
Paul & Moye-Rowley 2014). Studies have demonstrated 
Fig. 3: identification of the ABC transporter peptides from Candida glabrata (R) clinical isolate by electrospray ionisation (ESI)-MS/MS. 
(A) Plasma membrane preparations of control Saccharomyces cerevisiae mutant strains and clinical isolates separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as follows: 1- null mutant; 2- AD/124567 (Pdr5p ABC transporter of S. cerevisiae) (+); 
3- AD/CgCDR1 (CgCdr1p of C. glabrata); 4- AD/CgCDR2 (CgCdr2p of C. glabrata); 5- C. glabrata (R); 6- C. glabrata (S) and 7- C. glabrata 
ATCC2001. Excised bands correspond to molecular weight of 160kDa (ABC transporters). (B) ESI-MS/MS analysis identified peaks corre-
sponding to three different peptides in an ABC transporter protein. (C) Mascot algorithm analysis of three peptides led to the identification of 
a C. glabrata ABC transporter gene, CgCDR1.
Fig. 2: cytometry efflux assay of Saccharomyces cerevisiae controls 
(null mutant, AD/CaCDR1, AD/CgCDR1 or AD/CgCDR2), Candida 
glabrata resistant (R) and susceptible (S), ATCC 2001 Candida gla-
brata strains using R6G as fluorescent substrate in the presence and 
absence of glucose. The results are the average of the experiments 
performed in triplicate. Dark blue bar = no glucose; Light blue bar = 
with glucose. (*): p < 0,05.
ABC transporter and C. glabrata resistance • Debora Afonso Silva Rocha et al.6|7
that C. glabrata drug resistance occurs as a result of 
its haploid nature as well as the ability of rapid muta-
tion after exposure to azole agents (Safdar et al. 2002). 
This resistance phenotype can occur due to an altera-
tion of the target enzyme by the mutations/overexpres-
sion of its encoding gene or by overexpression of ABC 
transporters genes (CgCDR1, CgCDR2 or CgPDH1 and 
CgSNQ2). Increased gene expression leads to a higher 
protein level of these efflux pumps decreasing intracel-
lular drug concentration and as a consequence leads to 
resistance phenotype, accompanying broad range drug 
tolerance (Sanglard et al. 1995, Sanguinetti et al. 2005, 
Torelli et al. 2008, Morschhauser 2010). In this study, we 
analysed whether the mechanism of resistance of the C. 
glabrata clinical strain, isolated from blood samples, is 
correlated to an ABC transporter overexpression. Thus 
S. cerevisiae mutant strains overexpressing CaCDR1, 
CgCDR1 CgCDR2 genes and a null mutant as the sus-
ceptible control were used. Moreover, one susceptible C. 
glabrata clinical isolate which was collected from tra-
cheal secretion was also used.
For the susceptibility assays, in the present study we 
observed that the C. glabrata (R) clinical isolate was 
resistant to all azoles tested, including PSZ and VRZ, 
according to the CLSI M27-A3 protocol (Table I). Sev-
eral studies have demonstrated that there has been an 
increase of antifungal resistance cases for treatment and 
prophylaxis infections related to Candida spp. over the 
last few decades. (Almeida et al. 2013, Jiang et al. 2013). 
C. glabrata presents a greater propensity to develop 
azole resistance probably due to molecular mechanisms 
as increased and/or mutation expression of genes encod-
ing enzymes responsible for ergosterol biosynthesis; or 
this resistance can be enhanced by efflux pumps such 
as ABC proteins, a primary transporter responsible for 
active drug extrusion (Sanglard et al. 1995, Vermitsky & 
Edlind 2004, Torelli et al. 2008, Ge et al. 2010).
In order to evaluate the possible contribution of ABC 
transporters overexpression on resistance phenotype of 
this clinical strain (code 109), we performed a chemo-
sensitisation test using FK506, a classic ABC transport-
er inhibitor, in combination with different azoles (Egner 
& Kuchler 2000). This result demonstrated that different 
azoles (FCZ, ITZ, VRZ and PSZ) in combination with 
FK506 reverted the resistance phenotype of all resistant 
strains tested in the present study (S. cerevisiae mutant 
strains: AD/CaCDR1, AD/CgCDR1 and AD/CgCDR2 
and 109 clinical isolate) (Fig. 2, Table II). This outcome 
was expected for S. cerevisiae mutant strains since these 
isolates overexpress ABC transporters encoding genes. 
The chemosensitisation results of the 109 clinical isolate 
suggest that the overexpression of this efflux pumps is 
due to FK506 reversion.
Furthermore, a flow cytometry assay using R6G, a 
fluorescent substrate of ABC transporters, demonstrat-
ed that the 109 strain pumped out the fluorescent stain 
(46% of intracellular fluorescence, glucose (+), similarly 
to S. cerevisiae strain AD/CgCDR1 (51% of intracellular 
fluorescence) suggesting the overexpression of these ef-
flux pumps.
The identification of ABC proteins was confirmed 
by plasma membrane isolation, followed by SDS-PAGE 
and finally, ESI-MS/MS analysis. In lanes 2-5 (Fig. 3) a 
detectable band with an approximate molecular weight 
of 160 KDa that referred to ABC proteins according to 
identification by MS/MS was observed. The 109 clinical 
isolate (lane 5) excised band resulted in three different 
m/z peaks: 536.8 (+1), 532.8 (+2) and 639.9 (+2) where 
three peptides were identified: R.ASSIFSADFK.G, 
K.NEYVEAVIK.I and R.GLDSATALEFVR.A and 
which the Mascot algorithm software analysis identified 
as an ABC transporter protein, gene CgCDR1 of the C. 
glabrata specie. These data confirm the presence of ef-
flux proteins and their involvement in resistance pheno-
type of a C. glabrata clinical isolate extremely resistant 
to higher concentrations of all azoles tested.
Previous studies have shown increased expression lev-
els of ABC efflux pump genes in C. glabrata and their 
involvement in azole-resistant isolates of C. glabrata in 
hospital environments (Miyazaki et al. 1998, Sanglard et 
al. 2001, Sanguinetti et al. 2005). Our study emphasizes 
the importance to study this efflux pump due to its cor-
relation to high antifungal resistance in clinical isolates 
in developing countries. The high incidence of resistance 
phenotype in C. glabrata clinical isolates reveals the ur-
gent need to develop compounds responsible to inhibit or 
unsettle these ABC proteins in order to prevent drug ex-
trusion and as consequence a resistance profile.
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